| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7420057 | SPROUT PHARMS | Stable polymorph of flibanserin |
Aug, 2022
(1 year, 1 month ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9468639 | SPROUT PHARMS | Treating sexual desire disorders with flibanserin |
Oct, 2022
(11 months ago) | |
| US8227471 | SPROUT PHARMS | Treating sexual desire disorders with flibanserin |
May, 2023
(4 months ago) | |
| US7151103 | SPROUT PHARMS | Method of treating female hypoactive sexual desire disorder with flibanserin |
May, 2028
(4 years from now) | |
Addyi is owned by Sprout Pharms.
Addyi contains Flibanserin.
Addyi has a total of 4 drug patents out of which 3 drug patents have expired.
Expired drug patents of Addyi are:
- US9468639
- US8227471
- US7420057
Addyi was authorised for market use on 18 August, 2015.
Addyi is available in tablet;oral dosage forms.
Addyi can be used as use of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat hypoactive sexual desire disorder (hsdd).
The generics of Addyi are possible to be released after 09 May, 2028.
Drugs and Companies using FLIBANSERIN ingredient
Market Authorisation Date: 18 August, 2015
Treatment: Use of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat hypoactive sexual desire disorder (hsdd)
Dosage: TABLET;ORAL
ADDYI family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic